OBJECTIVE: Many studies of the treatment of obsessive-compulsive disorder (OCD) have used percent reduction cutoffs on the Yale-Brown Obsessive Compulsive Scale (YBOCS) to classify patients as treatment responders. However, reduction criteria have varied from 20% to 50%, with studies of cognitive-behavioral therapy (CBT) using a more stringent criterion than studies of pharmacotherapy. The aim of this retrospective investigation was to determine optimal YBOCS reduction criteria for classifying patients as responders. METHOD: Data from 87 adult clinic and research outpatients meeting DSM-IV-TR criteria for OCD according to structured interview were examined, comparing the percent YBOCS reduction from pretreatment to posttreatment with 2 "gold standard" criteria from the Clinical Global Impressions (CGI) scale: much or very much improved and mild illness or better. Signal detection analyses were used to determine the sensitivity, specificity, predictive value of a positive test, predictive value of a negative test, and efficiency of various YBOCS reduction cutoffs. RESULTS: A YBOCS reduction cutoff of 30% was optimal for predicting improvement on the CGI. The 20% cutoff used by many pharmacologic studies resulted in a high number of false positives, whereas the 50% cutoff used by most CBT studies resulted in a high number of false negatives. For predicting mild illness or better at posttreatment, a YBOCS reduction cutoff of 40% to 50% was optimal. CONCLUSIONS: A YBOCS reduction criterion of 30% appears to be optimal for determining clinical improvement, whereas a 40% to 50% reduction criterion is appropriate for predicting mild illness at posttreatment. Future studies should employ a standard definition of treatment response in order to facilitate cross-study comparisons.
OBJECTIVE: Many studies of the treatment of obsessive-compulsive disorder (OCD) have used percent reduction cutoffs on the Yale-Brown Obsessive Compulsive Scale (YBOCS) to classify patients as treatment responders. However, reduction criteria have varied from 20% to 50%, with studies of cognitive-behavioral therapy (CBT) using a more stringent criterion than studies of pharmacotherapy. The aim of this retrospective investigation was to determine optimal YBOCS reduction criteria for classifying patients as responders. METHOD: Data from 87 adult clinic and research outpatients meeting DSM-IV-TR criteria for OCD according to structured interview were examined, comparing the percent YBOCS reduction from pretreatment to posttreatment with 2 "gold standard" criteria from the Clinical Global Impressions (CGI) scale: much or very much improved and mild illness or better. Signal detection analyses were used to determine the sensitivity, specificity, predictive value of a positive test, predictive value of a negative test, and efficiency of various YBOCS reduction cutoffs. RESULTS: A YBOCS reduction cutoff of 30% was optimal for predicting improvement on the CGI. The 20% cutoff used by many pharmacologic studies resulted in a high number of false positives, whereas the 50% cutoff used by most CBT studies resulted in a high number of false negatives. For predicting mild illness or better at posttreatment, a YBOCS reduction cutoff of 40% to 50% was optimal. CONCLUSIONS: A YBOCS reduction criterion of 30% appears to be optimal for determining clinical improvement, whereas a 40% to 50% reduction criterion is appropriate for predicting mild illness at posttreatment. Future studies should employ a standard definition of treatment response in order to facilitate cross-study comparisons.
Authors: Carolyn I Rodriguez; James Bender; Sue M Marcus; Michael Snape; Moira Rynn; Helen Blair Simpson Journal: J Clin Psychiatry Date: 2010-09 Impact factor: 4.384
Authors: Eric A Storch; Alessandro S De Nadai; Adam B Lewin; Joseph F McGuire; Anna M Jones; P Jane Mutch; R Doug Shytle; Tanya K Murphy Journal: J Child Adolesc Psychopharmacol Date: 2011-11-09 Impact factor: 2.576
Authors: Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March Journal: JAMA Date: 2011-09-21 Impact factor: 56.272
Authors: Adam M Reid; Joseph P H McNamara; Tanya K Murphy; Andrew G Guzick; Eric A Storch; Wayne K Goodman; Gary R Geffken; Regina Bussing Journal: J Psychiatr Res Date: 2015-10-14 Impact factor: 4.791
Authors: David Mataix-Cols; Lorena Fernández de la Cruz; Ashley E Nordsletten; Fabian Lenhard; Kayoko Isomura; Helen Blair Simpson Journal: World Psychiatry Date: 2016-02 Impact factor: 49.548
Authors: Sangchoon Jeon; John T Walkup; Douglas W Woods; Alan Peterson; John Piacentini; Sabine Wilhelm; Lily Katsovich; Joseph F McGuire; James Dziura; Lawrence Scahill Journal: Contemp Clin Trials Date: 2013-08-31 Impact factor: 2.226
Authors: Sophie A Palitz; Nicole E Caporino; Joseph F McGuire; John Piacentini; Anne Marie Albano; Boris Birmaher; John T Walkup; Scott N Compton; Golda S Ginsburg; Philip C Kendall Journal: J Am Acad Child Adolesc Psychiatry Date: 2018-04-17 Impact factor: 8.829
Authors: Nicole E Caporino; Dara Sakolsky; Douglas M Brodman; Joseph F McGuire; John Piacentini; Tara S Peris; Golda S Ginsburg; John T Walkup; Satish Iyengar; Philip C Kendall; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2017-06-06 Impact factor: 8.829